----

----

| x      | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |
|--------|------------------------------------------------------------------------------------------|
|   |                                                                                     |
|   | For the quarterly period ended January 31, 2011                                          |
|   |                                                                                     |
|   | OR                                                                                       |
|   |                                                                                     |
|  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

|   | Large accelerated filer |  ̈ |   | Accelerated filer         |  ̈ |
|--------|-------------------------|--------|--------|---------------------------|--------|
|   |                    |   |   |                      |   |
|   | Non-accelerated filer   |  ̈ |   | Smaller reporting company | x      |

----

----

----

|                                                                                                                                                                                                                          | Pages           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Condensed Consolidated Balance Sheets as of January 31, 2011 (unaudited) and October 31, 2010                                                                                                                                 | F-1             |
|                                                                                                                                                                                                                          |            |
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended January 31, 2011 and 2010 (unaudited) and the period from inception September 25, 2002 through January 31, 2011 (unaudited) | F-2             |
|                                                                                                                                                                                                                          |            |
| Condensed Consolidated Statements of Stockholders’ Deficiency for the period from inception September 25, 2002 through January 31, 2011 (unaudited)                                                                     | F-3             |
|                                                                                                                                                                                                                          |            |
| Condensed Consolidated Statements of Cash Flows for the three months ended January 31, 2011 and 2010 (unaudited) and the period from inception September 25, 2002 through January 31, 2011 (unaudited)                        | F-4             |
|                                                                                                                                                                                                                          |            |
| Notes to Condensed Consolidated Financial Statements (unaudited)                                                                                                                                                              | F-5 – F-8 |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. ("ABMT") |
|-------------------------------------------------|
| AND SUBSIDIARIES                                |
| (A DEVELOPMENT STAGE COMPANY)                   |
| CONDENSED CONSOLIDATED BALANCE SHEETS           |

| ASSETS                                                             |
|--------------------------------------------------------------------|
|                                                               |   | January 31, |   |   | October 31, |   |
|                                                               |   | 2011 |   |   | 2010 |   |
|                                                               |   | Unaudited |   |   |   |   |
|                                                               |   |   |   |   |   |   |
| CURRENT ASSETS                                                     |   |   |   |   |   |   |
| Cash and cash equivalents                                          |   | $ | 16,130 |   |   | $ | 38,614 |   |
| Other receivables and prepaid expenses                             |   |   | 13,364 |   |   |   | 12,623 |   |
| Total Current Assets                                               |   |   | 29,494 |   |   |   | 51,237 |   |
|                                                               |   |   |   |   |   |   |   |   |
| PROPERTY AND EQUIPMENT, NET                                        |   |   | 48,753 |   |   |   | 49,461 |   |
| TOTAL ASSETS                                                       |   | $ | 78,247 |   |   | $ | 100,698 |   |
|                                                               |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                              |
|                                                               |   |   |   |   |   |   |   |   |
| CURRENT LIABILITIES                                                |   |   |   |   |   |   |   |   |
| Other payables and accrued expenses                                |   | $ | 19,559 |   |   | $ | 25,711 |   |
| Due to a stockholder                                               |   |   | 99,104 |   |   |   | 217,951 |   |
| Due to directors                                                   |   |   | 144,047 |   |   |   | 158,941 |   |
| Due to a related company                                           |   |   | 405,572 |   |   |   | 400,192 |   |
| Due to related parties                                             |   |   | 765,627 |   |   |   | 788,400 |   |
| Total Current Liabilities                                          |   |   | 1,433,909 |   |   |   | 1,591,195 |   |
|                                                               |   |   |   |   |   |   |   |   |
|                                                               |   |   |   |   |   |   |   |   |
| COMMITMENTS AND CONTINGENCIES                                      |   |   | - |   |   |   | - |   |
|                                                               |   |   |   |   |   |   |   |   |
| DEFICIT                                                            |   |   |   |   |   |   |   |   |
| ABMT Stockholders' Deficit                                         |   |   |   |   |   |   |   |   |
| Common stock, $0.00001 par value, 100,000,000 shares               |   |   |   |   |   |   |   |   |
| authorized,  56,374,850 and 56,144,850 shares            |   |   |   |   |   |   |   |   |
| issued and outstanding as of January 31, 2011 and October 31, 2010 |   |   | 564 |   |   |   | 562 |   |
| Common stock, 230,000 shares to be issued                          |   |   | - |   |   |   | 2 |   |
| Stock subscription receivable                                      |   |   | - |   |   |   | (230,000 | ) |
| Additional paid-in capital                                         |   |   | 1,501,391 |   |   |   | 1,494,551 |   |
| Deferred stock compensation                                        |   |   | (143,334 | ) |   |   | (206,459 | ) |
| Accumulated deficit during development stage                       |   |   | (2,584,318 | ) |   |   | (2,436,044 | ) |
| Accumulated other comprehensive loss                               |   |   | (129,965 | ) |   |   | (113,109 | ) |
| Total ABMT Stockholders' Deficit                                   |   |   | (1,355,662 | ) |   |   | (1,490,497 | ) |
|                                                               |   |   |   |   |   |   |   |   |
| Noncontrolling interests                                           |   |   |   |   |   |   |   |   |
| Total Deficit                                                      |   |   | (1,355,662 | ) |   |   | (1,490,497 | ) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                        |   | $ | 78,247 |   |   | $ | 100,698 |   |

| The accompanying notes are an integral part of these condensed consolidated financial statements |
|--------------------------------------------------------------------------------------------------|

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES                |
|------------------------------------------------------------------------|
| (A DEVELOPMENT STAGE COMPANY)                                          |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
| (UNAUDITED)                                                            |

|                                              |   | Three months ended |       |    | September 25, 2002  |   |
|---------------------------------------------------|--------|--------------------|------------|---------|---------------------|--------|
|                                              |   | January 31,        |       |    | (Inception) through |   |
|                                              |   | 2011               |       |    | 2010                |   |   | January 31, 2010 |   |
|                                              |   |               |       |    |                |   |   |   |   |
| OPERATING EXPENSES                                |   |               |       |    |                |   |   |   |   |
| General and administrative expenses               |   | $                  | 125,853    |    |                | $      | 144,600 |   |   | $ | 2,108,222 |   |
| Depreciation                                      |   |               | 1,308      |    |                |   | 7,452 |   |   |   | 262,678 |   |
| Research and development (Net of                  |   |               |       |    |                |   |   |   |   |   |   |   |
|   government grant)                     |   |               | 30         |    |                |   | 1,840 |   |   |   | 119,063 |   |
| Total Operating Expenses                          |   |               | 127,191    |    |                |   | 153,892 |   |   |   | 2,489,963 |   |
|                                              |   |               |       |    |                |   |   |   |   |   |   |   |
| LOSS FROM OPERATIONS                              |   |               | (127,191   | )       |                |   | (153,892 | ) |   |   | (2,489,963 | ) |
|                                              |   |               |       |    |                |   |   |   |   |   |   |   |
| OTHER INCOME (EXPENSES)                           |   |               |       |    |                |   |   |   |   |   |   |   |
| Other income                                      |   |               | 908        |    |                |   | - |   |   |   | 5,493 |   |
| Interest income                                   |   |               | 24         |    |                |   | 13 |   |   |   | 1,625 |   |
| Interest paid to a stockholder                    |   |               |       |    |                |   |   |   |   |   |   |   |
|   and related parties                   |   |               | (14,826    | )       |                |   | (12,831 | ) |   |   | (115,221 | ) |
| Imputed interest                                  |   |               | (6,840     | )       |                |   | (7,388 | ) |   |   | (183,924 | ) |
| Other expenses                                    |   |               | (349       | )       |                |   | (293 | ) |   |   | (19,533 | ) |
| Total Other Expenses, net                         |   |               | (21,083    | )       |                |   | (20,499 | ) |   |   | (311,560 | ) |
|                                              |   |               |       |    |                |   |   |   |   |   |   |   |
| LOSS FROM OPERATIONS BEFORE TAXES                 |   |               | (148,274   | )       |                |   | (174,391 | ) |   |   | (2,801,523 | ) |
| Income tax expense                                |   |               | -          |    |                |   | - |   |   |   | - |   |
| NET LOSS                                          |   |               | (148,274   | )       |                |   | (174,391 | ) |   |   | (2,801,523 | ) |
| Net loss attributable to noncontrolling interests |   |               | -          |    |                |   | - |   |   |   | 217,205 |   |
| NET LOSS ATTRIBUTABLE TO ABMT                     |   |               |       |    |                |   |   |   |   |   |   |   |
| COMMON STOCKHOLDERS                               |   |               | (148,274   | )       |                |   | (174,391 | ) |   |   | (2,584,318 | ) |
|                                              |   |               |       |    |                |   |   |   |   |   |   |   |
| OTHER COMPREHENSIVE (LOSS) INCOME                 |   |               |       |    |                |   |   |   |   |   |   |   |
| Total other comprehensive (loss) income           |   |               | (16,856    | )       |                |   | 44 |   |   |   | (129,965 | ) |
| Add: foreign currency translation loss            |   |               |       |    |                |   |   |   |   |   |   |   |
| attributable to noncontrolling interest           |   |               | -          |    |                |   | - |   |   |   | - |   |
| Foreign currency translation (loss) income        |   |               |       |    |                |   |   |   |   |   |   |   |
| attributable to ABMT common stockholders          |   |               | (16,856    | )       |                |   | 44 |   |   |   | (129,965 | ) |
| COMPREHENSIVE LOSS ATTRIBUTABLE                   |   |               |       |    |                |   |   |   |   |   |   |   |
| TO ABMT COMMON STOCKHOLDERS                       |   | $                  | (165,130   | )       |                | $      | (174,347 | ) |   | $ | (2,714,283 | ) |
|                                              |   |               |       |    |                |   |   |   |   |   |   |   |
| Net loss per share-basic and diluted              |   | $                  | (0.00      | )  |                | $      | (0.00 | )  |   |   |   |   |
|                                              |   |               |       |    |                |   |   |   |   |   |   |   |
| Weighted average number of shares                 |   |               |       |    |                |   |   |   |   |   |   |   |
| outstanding during the period                     |   |               |       |    |                |   |   |   |   |   |   |   |
| - basic and diluted                               |   |               | 56,374,850 |    |                |   | 55,732,159 |   |   |   |   |   |

| The accompanying notes are an integral part of these condensed consolidated financial statements |
|--------------------------------------------------------------------------------------------------|

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES                         |
|---------------------------------------------------------------------------------|
| (A DEVELOPMENT STAGE COMPANY)                                                   |
| CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY (UNAUDITED) |

|                                                              |   | Common Stock     |       |   | Shares to be issued |   |   | Stock            |   |   | Additional |   |   | Deferred                 |   |   | Accumulated deficit during |   |     | Accumulated other  |   |   |              |   |   |               |     |
|-------------------------------------------------------------------|--------|------------------|------------|--------|---------------------|--------|--------|------------------|--------|--------|------------|--------|--------|--------------------------|--------|--------|----------------------------|--------|----------|--------------------|--------|--------|-------------------|--------|--------|--------------------|----------|
|                                                              |   | Number of Shares |       |   | Amount              |   |   | Number of Shares |   |   | Amount     |   |   | Subscriptions receivable |   |   | Paid-in capital            |   |     | Stock Compensation |   |   | Development stage |   |   | Comprehensive loss |     |   | Noncontrolling interests |   |   | Total |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |
| Stock issued to founders for cash                                 |   |             | 50,510,000 |   |                | $      | 505    |             |   |   | -          |   |   | $                        | -      |   |                       | $      | -        |               |   | $      | 275,002           |   |   | $                  | -        |   |   | $ | - |   |   | $ | - |   |   | $ | 217,205 |   |   | $ | 492,712 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                           |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | (40,343 | ) |   |   | - |   |   |   | (17,290 | ) |   |   | (57,633 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | (225 | ) |   |   | 10 |   |   |   | (215 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (57,848 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2003                                      |   |             | 50,510,000 |   |                |   | 505    |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 275,002           |   |   |               | -        |   |   |   | (40,343 | ) |   |   | (225 | ) |   |   | 199,925 |   |   |   | 434,864 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                             |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | (65,960 | ) |   |   | - |   |   |   | (28,269 | ) |   |   | (94,229 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | (357 | ) |   |   | 2 |   |   |   | (355 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (94,584 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2004                                      |   |             | 50,510,000 |   |                |   | 505    |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 275,002           |   |   |               | -        |   |   |   | (106,303 | ) |   |   | (582 | ) |   |   | 171,658 |   |   |   | 340,280 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder                   |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| and related company                                               |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 23,103            |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 23,103 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                             |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | (357,863 | ) |   |   | - |   |   |   | (153,370 | ) |   |   | (511,233 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | (12,290 | ) |   |   | 2,064 |   |   |   | (10,226 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (521,459 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2005                                      |   |             | 50,510,000 |   |                |   | 505    |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 298,105           |   |   |               | -        |   |   |   | (464,166 | ) |   |   | (12,872 | ) |   |   | 20,352 |   |   |   | (158,076 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder                   |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| and related company                                               |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 27,184            |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 27,184 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                             |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | (172,738 | ) |   |   | - |   |   |   | (18,276 | ) |   |   | (191,014 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | (6,084 | ) |   |   | (2,076 | ) |   |   | (8,160 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (199,174 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2006                                      |   |             | 50,510,000 |   |                |   | 505    |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 325,289           |   |   |               | -        |   |   |   | (636,904 | ) |   |   | (18,956 | ) |   |   | - |   |   |   | (330,066 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder,                  |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| related company and related party                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 39,021            |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 39,021 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                             |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | (196,871 | ) |   |   | - |   |   |   | - |   |   |   | (196,871 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | (27,401 | ) |   |   | - |   |   |   | (27,401 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (224,272 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2007                                      |   |             | 50,510,000 |   |                |   | 505    |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 364,310           |   |   |               | -        |   |   |   | (833,775 | ) |   |   | (46,357 | ) |   |   | - |   |   |   | (515,317 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder                   |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| and related company                                               |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 27,764            |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 27,764 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                           |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | (227,038 | ) |   |   | - |   |   |   | - |   |   |   | (227,038 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | (35,833 | ) |   |   | - |   |   |   | (35,833 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (262,871 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31,2008                                        |   |             | 50,510,000 |   |                |   | 505    |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 392,074           |   |   |               | -        |   |   |   | (1,060,813 | ) |   |   | (82,190 | ) |   |   | - |   |   |   | (750,424 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Recapitalization                                                  |   |             | 5,104,000  |   |                |   | 51     |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | (51               | )      |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($3.05 per share)                       |   |             | 100,000    |   |                |   | 1      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 304,999           |   |   |               | (292,292 | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 12,708 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.15 per share)      |   |             | 5,000      |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 5,750             |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 5,750 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.15 per share)      |   |             | 2,000      |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 2,300             |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 2,300 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Contributed capital                                               |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 26,950            |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 26,950 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Distributed to the stockholders                                   |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | (31,409           | )      |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (31,409 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed Interest on advances from a stockholder                   |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| and related company                                               |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 31,656            |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 31,656 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                             |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | (558,432 | ) |   |   | - |   |   |   | - |   |   |   | (558,432 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | (1,856 | ) |   |   | - |   |   |   | (1,856 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (560,288 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31, 2009                                       |   |             | 55,721,000 |   |                |   | 557    |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 732,269           |   |   |               | (292,292 | ) |   |   | (1,619,245 | ) |   |   | (84,046 | ) |   |   | - |   |   |   | (1,262,757 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.5 per share)       |   |             | 6,667      |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 10,000            |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 10,000 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.5 per share)       |   |             | 16,667     |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 25,000            |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 25,000 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.5 per share)       |   |             | 136,833    |   |                |   | 2      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 205,248           |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 205,250 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock to be issued for cash in private placement ($1.0 per share) |   |             | -          |   |                |   | -      |             |   |   | 230,000    |   |   |                     | 2      |   |                       |   | (230,000 | )                  |   |   | 229,998           |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                          |   |             | 100,000    |   |                |   | 1      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 99,999            |   |   |               | (100,000 | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                          |   |             | 13,683     |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 13,683            |   |   |               | (13,683  | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                          |   |             | 150,000    |   |                |   | 2      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 149,998           |   |   |               | (150,000 | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                        |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | 349,516  |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 349,516 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder                   |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| and related company                                               |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 28,356            |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 28,356 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                             |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | (816,799 | ) |   |   | - |   |   |   | - |   |   |   | (816,799 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | (29,063 | ) |   |   | - |   |   |   | (29,063 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (845,862 | ) |
| Balance at October 31, 2010                                       |   |             | 56,144,850 |   |                |   | 562    |             |   |   | 230,000    |   |   |                     | 2      |   |                       |   | (230,000 | )                  |   |   | 1,494,551         |   |   |               | (206,459 | ) |   |   | (2,436,044 | ) |   |   | (113,109 | ) |   |   | - |   |   |   | (1,490,497 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1 per share)         |   |             | 230,000    |   |                |   | 2      |             |   |   | (230,000   | )      |   |                     | (2     | )      |                       |   | 230,000  |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 230,000 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder                   |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| and related company                                               |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | 6,840             |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 6,840 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                        |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | 63,125   |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 63,125 |   |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                      |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | (148,274 | ) |   |   | - |   |   |   | - |   |   |   | (148,274 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                 |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | (16,856 | ) |   |   | - |   |   |   | (16,856 | ) |
|                                                              |   |             |       |   |                |   |   |             |   |   |       |   |   |                     |   |   |                       |   |     |               |   |   |              |   |   |               |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                |   |             | -          |   |                |   | -      |             |   |   | -          |   |   |                     | -      |   |                       |   | -        |               |   |   | -                 |   |   |               | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (165,130 | ) |
| Balance at January 31, 2011                                       |   |             | 56,374,850 |   |                | $      | 564    |             |   |   | -          |   |   | $                        | -      |   |                       | $      | -        |               |   | $      | 1,501,391         |   |   | $                  | (143,334 | ) |   | $ | (2,584,318 | ) |   | $ | (129,965 | ) |   | $ | - |   |   | $ | (1,355,662 | ) |

| The accompanying notes are an integral part of these condensed consolidated financial statements |
|--------------------------------------------------------------------------------------------------|

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES |
|---------------------------------------------------------|
| (A DEVELOPMENT STAGE COMPANY)                           |
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS         |
| (UNAUDITED)                                             |

|                                                  |   | Three months ended |     |   | September 25, 2002  |   |
|-------------------------------------------------------|--------|--------------------|----------|--------|---------------------|--------|
|                                                  |   | January 31,        |     |   | (inception) through |   |
|                                                  |   | 2011               |     |   | 2010                |   |   | January 31, 2010 |   |
|                                                  |   |               |     |   |                |   |   |   |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                  |   |               |     |   |                |   |   |   |   |
| Net loss                                              |   | $                  | (148,274 | )      |                | $      | (174,391 | ) |   | $ | (2,584,318 | ) |
| Adjustments to reconcile net loss to cash             |   |               |     |   |                |   |   |   |   |   |   |   |
| used in operating activities:                         |   |               |     |   |                |   |   |   |   |   |   |   |
| Depreciation                                          |   |               | 1,308    |   |                |   | 7,452 |   |   |   | 262,678 |   |
| Loss on disposal of fixed assets                      |   |               | -        |   |                |   | - |   |   |   | 5,327 |   |
| Stock issued for services                             |   |               | 63,125   |   |                |   | 38,125 |   |   |   | 425,350 |   |
| Noncontrolling interests                              |   |               | -        |   |                |   | - |   |   |   | (217,205 | ) |
| Imputed interest                                      |   |               | 6,840    |   |                |   | 7,388 |   |   |   | 183,924 |   |
| Changes in operating assets and liabilities           |   |               |     |   |                |   |   |   |   |   |   |   |
| (Increase) decrease in:                               |   |               |     |   |                |   |   |   |   |   |   |   |
| Other receivables and prepaid expenses                |   |               | (566     | )      |                |   | - |   |   |   | (13,364 | ) |
| Increase (decrease) in:                               |   |               |     |   |                |   |   |   |   |   |   |   |
| Other payables and accrued expenses                   |   |               | (6,205   | )      |                |   | 6,114 |   |   |   | 19,559 |   |
| Net cash used in operating activities                 |   |               | (83,772  | )      |                |   | (115,312 | ) |   |   | (1,918,049 | ) |
|                                                  |   |               |     |   |                |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                  |   |               |     |   |                |   |   |   |   |   |   |   |
| Purchase of property and equipment                    |   |               | -        |   |                |   | (4,389 | ) |   |   | (316,759 | ) |
| Due from a related party                              |   |               | -        |   |                |   | - |   |   |   | - |   |
| Due from stockholders                                 |   |               | -        |   |                |   | - |   |   |   | - |   |
| Due from a noncontrolling stockholder of a subsidiary |   |               | -        |   |                |   | 766 |   |   |   | - |   |
| Net cash used in investing activities                 |   |               | -        |   |                |   | (3,623 | ) |   |   | (316,759 | ) |
|                                                  |   |               |     |   |                |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                  |   |               |     |   |                |   |   |   |   |   |   |   |
| Stock issued to founders                              |   |               | -        |   |                |   | - |   |   |   | 505 |   |
| Proceeds from issuance of shares                      |   |               | 230,000  |   |                |   | 35,000 |   |   |   | 478,300 |   |
| Contribution by stockholders                          |   |               | -        |   |                |   | - |   |   |   | 519,157 |   |
| Distributed to stockholders                           |   |               | -        |   |                |   | - |   |   |   | (31,409 | ) |
| Due to a stockholder                                  |   |               | (118,352 | )      |                |   | 6,560 |   |   |   | 99,104 |   |
| Due to directors                                      |   |               | (16,832  | )      |                |   | (18,530 | ) |   |   | 144,047 |   |
| Due to a related company                              |   |               | -        |   |                |   | - |   |   |   | 405,572 |   |
| Due to related parties                                |   |               | (32,963  | )      |                |   | 114,531 |   |   |   | 765,627 |   |
| Net cash provided by financing activities             |   |               | 61,853   |   |                |   | 137,561 |   |   |   | 2,380,903 |   |
|                                                  |   |               |     |   |                |   |   |   |   |   |   |   |
| EFFECT ON EXCHANGE RATES ON CASH                      |   |               | (565     | )      |                |   | (11 | ) |   |   | (129,965 | ) |
|                                                  |   |               |     |   |                |   |   |   |   |   |   |   |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS  |   |               | (22,484  | )      |                |   | 18,615 |   |   |   | 16,130 |   |
|                                                  |   |               |     |   |                |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD      |   |               | 38,614   |   |                |   | 10,606 |   |   |   | - |   |
|                                                  |   |               |     |   |                |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD            |   | $                  | 16,130   |   |                | $      | 29,221 |   |   | $ | 16,130 |   |

| The accompanying notes are an integral part of these condensed consolidated financial statements |
|--------------------------------------------------------------------------------------------------|

----

----

|   | (1) | The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

----

|   | 1. | A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care; |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit; |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------|

|   | 3. | Improving the biological activity of materials. Clinical trial results have shown that as PA implants degrade, they promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to 'stress shielding'; |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | Reducing the chance of post-operative infection; |
|--------|----|--------------------------------------------------|

|   | 5. | Effectively controlling the degeneration speed, so that there will be no complications in treating repeat injuries; |
|--------|----|---------------------------------------------------------------------------------------------------------------------|

|   | 6. | Ease of post-operative care i.e. no distortion during x-ray imaging; |
|--------|----|----------------------------------------------------------------------|

|   | 7. | Simple and cost-effective to manufacture. |
|--------|----|-------------------------------------------|

----

----

| Estimate current production lines in full capacity |   |   |                   |   |
|----------------------------------------------------|--------|--------|------------------------|--------|
|                                               |   |   | Output Quantity (Max.) |   |   | Price at ex-factory (U$) |   |   | Total Turnover (U$) |
| PA Screw                                           |   |   | 100,000                |   | (piece) |   |   | 180 |   |   |   |   | 18,000,000 |
| PA Binding Wire                                    |   |   | 240,000                |   | (pack) |   |   | 50 |   |   |   |   | 12,000,000 |
|                                               |   |   |                   |   |   |   |   |   |   | Total: |   |   | 30,000,000 |

----

----

| Statistic and Census report by Ministry of Health of People's Republic of China. |
|----------------------------------------------------------------------------------|
| (Year 2009)                                                                      |
|                                                                             |   |   |   |   | Total | Total |
|                                                                             | Total | Government | Society | Private | Non-Profit | Profit |
| Hospitals                                                                        | 19712 | 9777 | 6048 | 3887 | 15650 | 4038 |
|    General Hospital                                               | 13119 | 5830 | 5060 | 2229 | 10856 | 2245 |
|    TCM Hospital                                                   | 2688 | 2244 | 158 | 286 | 2403 | 285 |
|    TCM-WM Hospital                                                | 236 | 96 | 48 | 92 | 139 | 97 |
|    Minority Hospital                                              | 191 | 170 | 8 | 13 | 175 | 16 |
|    Specialist Hospital                                            | 3437 | 1422 | 763 | 1252 | 2048 | 1383 |
|    Nursing Hospital                                               | 41 | 15 | 11 | 15 | 29 | 12 |

----

|                       |   | Three months ended |   |   | September 25, 2002  |   |
|----------------------------|--------|--------------------|--------|--------|---------------------|--------|
|                       |   | January 31,        |   |   | (Inception) through |   |
|                       |   | 2011               |   |   | 2010                |   |   | January 31, 2011 |   |
| Interest paid to directors |   |               |   |   |                |   |   |   |   |
| and a related company      |   | $                  | (6,840 | )      |                |   | (7,388 | ) |   |   | (183,924 | ) |

----

----

|   | 1. | Property and equipment |
|--------|----|------------------------|

|   | 2. | Long-lived assets |
|--------|----|-------------------|

|   | 3. | Fair value of financial instruments |
|--------|----|-------------------------------------|

|   | 4. | Government  grant |
|--------|----|-----------------------------|

|   | 5. | Income taxes |
|--------|----|--------------|

----

|   | 6. | Research and Development |
|--------|----|--------------------------|

|   | 7. | Foreign currency translation |
|--------|----|------------------------------|

----

----

----

----

| Exhibit No. | Description                                            |
|-------------|--------------------------------------------------------|
|        |                                                   |
| 3.1         | Articles of Incorporation (1)                          |
| 3.2         | Bylaws (1)                                             |
| 31.1        | Section 302 Certification of Chief Executive Officer*  |
| 31.2        | Section 302 Certification of Chief Financial Officer * |
| 32.1        | Section 906 Certification of Chief Executive Officer * |
| 32.2        | Section 906 Certification of Chief Financial Officer * |

----

|   | By:    |                                   |
|--------|--------|----------------------------------------|
|   |   | ADVANCED BIOMEDICAL TECHNOLOGIES, INC. |
|   |   |                                   |
|   |   | By:                                    | /s/ Chi Ming YU |
|   |   | Name:                                  | Chi Ming YU |
|   |   | Title:                                 | President and Director |

|   |   | By:    | /s/ Wang Hui                         |
|--------|--------|--------|--------------------------------------|
|   |   | Name:  | Wang Hui                             |
|   |   | Title: | Director and Chief Executive Officer |

|   |   | By:    | /s/ Kai GUI                                     |
|--------|--------|--------|-------------------------------------------------|
|   |   | Name:  | Kai GUI                                         |
|   |   | Title: | Director, Secretary and Chief Financial Officer |